

CITATION REPORT

List of articles citing

2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations

DOI: 10.1016/s0828-282x(09)70715-9

Canadian Journal of Cardiology, 2009, 25, 567-79.

Source: <https://exaly.com/paper-pdf/47080412/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|-----|--|----|-----------|
| 608 | Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia. 2009 , 8, 56 | | 5 |
| 607 | Simplifying the approach to the management of dyslipidemia. 2009 , 302, 2148-9 | | 8 |
| 606 | Non-HDL C equals apolipoprotein B: except when it does not!. 2010 , 21, 518-24 | | 25 |
| 605 | Current world literature. 2010 , 21, 539-42 | | |
| 604 | Statins for primary prevention in older adults: who is high risk, who is old, and what denotes primary prevention?. 2010 , 152, 528-30, W183 | | 6 |
| 603 | ACP Journal Club. Perioperative fluvastatin reduced cardiac events after noncardiac vascular surgery. 2010 , 152, JC1-7 | | |
| 602 | High-density lipoproteins and cardiovascular disease: 2010 update. 2010 , 8, 413-23 | | 27 |
| 601 | Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. 2010 , 6, 335-46 | | 81 |
| 600 | Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. 2010 , 53, 1846-55 | | 54 |
| 599 | Revisiting dietary cholesterol recommendations: does the evidence support a limit of 300 mg/d?. 2010 , 12, 377-83 | | 43 |
| 598 | Assessment of cardiovascular risk. 2010 , 12, 384-93 | | 11 |
| 597 | Canadian Society of Transplantation and Canadian Society of Nephrology commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients. 2010 , 56, 219-46 | | 37 |
| 596 | Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). 2010 , 106, 204-9 | | 112 |
| 595 | The JUPITER Trial: responding to the critics. 2010 , 106, 1351-6 | | 23 |
| 594 | Uncoupling protein 2 G(-866)A polymorphism: a new gene polymorphism associated with C-reactive protein in type 2 diabetic patients. 2010 , 9, 68 | | 11 |
| 593 | The preventing recurrent vascular events and neurological worsening through intensive organized case-management (PREVENTION) trial protocol [clinicaltrials.gov identifier: NCT00931788]. 2010 , 5, 27 | | 9 |
| 592 | Feedback GAP: study protocol for a cluster-randomized trial of goal setting and action plans to increase the effectiveness of audit and feedback interventions in primary care. 2010 , 5, 98 | | 22 |

| | | |
|-----|---|-----|
| 591 | Attainment of Canadian and European guidelines' lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin. 2010 , 64, 1765-72 | 3 |
| 590 | Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective. 2010 , 4, 383-413 | 76 |
| 589 | Symptomatic Coronary Artery Disease: A Call to Action for Pharmacists. 2010 , 143, 302-308 | |
| 588 | Statin therapy for low-LDL, high-hsCRP patients: from JUPITER to CORONA. 2010 , 56, 505-7 | 7 |
| 587 | Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk". 2010 , 3, 447-52 | 47 |
| 586 | Update on the efficacy and safety of combination ezetimibe plus statin therapy. 2010 , 5, 655-684 | 28 |
| 585 | Manejo poblacional de las dislipidemias primarias. 2010 , 21, 705-713 | 1 |
| 584 | Establishing a clinical basis for hsCRP in the prevention and treatment of cardiovascular disease. 2010 , 56, 1186-7 | 6 |
| 583 | Northern light: a commentary on the 2009 Canadian Guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in adults. 2010 , 56, 502-4 | |
| 582 | By Jove! What is a clinician to make of JUPITER?. 2010 , 170, 1073-7 | 40 |
| 581 | Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER. 2010 , 26, 2485-97 | 14 |
| 580 | Rolle der Inflammation in der Atherosklerose [Ein Update. 2010 , 39, 140-146 | 2 |
| 579 | Using apolipoprotein B to manage dyslipidemic patients: time for a change?. 2010 , 85, 440-5 | 45 |
| 578 | Effects of eggs on plasma lipoproteins in healthy populations. 2010 , 1, 156-60 | 43 |
| 577 | Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients. 2010 , 4, 272-8 | 10 |
| 576 | Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugs. 2010 , 70, 1363-79 | 38 |
| 575 | Cardiovascular risk-estimation systems in primary prevention: do they differ? Do they make a difference? Can we see the future?. 2010 , 122, 300-10 | 155 |
| 574 | Cardiovascular diseases. Introduction. 2010 , 11, 1-2 | 6 |

| | | | |
|-----|--|-----|-----|
| 573 | Pitavastatin - from clinical trials to clinical practice. 2010 , 11, 15-22 | | 14 |
| 572 | C-reactive protein measurement and cardiovascular disease [Authors' reply. 2010 , 375, 1077-1078 | | 1 |
| 571 | The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. <i>Canadian Journal of Cardiology</i> , 2010 , 26, 249-58 | 3.8 | 131 |
| 570 | Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS). <i>Canadian Journal of Cardiology</i> , 2010 , 26, e330-5 | 3.8 | 40 |
| 569 | C-reactive protein: risk factor, biomarker and/or therapeutic target?. <i>Canadian Journal of Cardiology</i> , 2010 , 26 Suppl A, 41A-44A | 3.8 | 72 |
| 568 | Addressing poor nutrition to promote heart health: moving upstream. <i>Canadian Journal of Cardiology</i> , 2010 , 26 Suppl C, 21C-4C | 3.8 | 18 |
| 567 | Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency. 2010 , 9, 127 | | 4 |
| 566 | Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes. 2010 , 9, 80 | | 11 |
| 565 | Interpretation of Mendelian randomization studies and the search for causal pathways in atherothrombosis: the need for caution. 2010 , 8, 465-9 | | 4 |
| 564 | Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R(3)i). 2010 , 26, 1793-7 | | 36 |
| 563 | Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. 2011 , 32, 1345-61 | | 793 |
| 562 | Prevalence of low high-density lipoprotein cholesterol (HDL-C) as a marker of residual cardiovascular risk among acute coronary syndrome patients from Oman. 2011 , 27, 879-85 | | 7 |
| 561 | Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis. 2011 , 27, 1067-78 | | 5 |
| 560 | Prevention of metabolic syndrome in serious mental illness. 2011 , 34, 109-25 | | 15 |
| 559 | Opening a new lipid "apo-theary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk. 2011 , 86, 762-80 | | 25 |
| 558 | The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels. 2011 , 57, 784-91 | | 29 |
| 557 | Systematic review of guidelines on imaging of asymptomatic coronary artery disease. 2011 , 57, 1591-600 | | 52 |
| 556 | Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math. 2011 , 58, 457-63 | | 118 |

| | | | |
|-----|---|-----|-----|
| 555 | Potential effects on clinical management of treatment algorithms on the basis of apolipoprotein-B/A-1 and total/high-density lipoprotein-cholesterol ratios. 2011 , 5, 159-165 | | 4 |
| 554 | Clinical perspective: have the results of recent clinical trials of lipid-lowering therapies influenced the way we should practice? A Latin American perspective of current issues in clinical lipidology. 2011 , 5, 124-132 | | 3 |
| 553 | The population effects of the global cardiovascular risk model in United States adults: findings from the National Health and Nutrition Surveys, 2005-2006. 2011 , 5, 166-172 | | 5 |
| 552 | Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of low-density lipoprotein and nonhigh-density lipoprotein cholesterol with apolipoprotein B in mixed dyslipidemic patients. 2011 , 5, 179-187 | | 5 |
| 551 | Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. 2011 , 5, S18-29 | | 90 |
| 550 | Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without chronic kidney disease. <i>Journal of the American Medical Association</i> , 2011 , 305, 171-82 | | 17 |
| 549 | Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. 2011 , 5, 338-67 | | 201 |
| 548 | Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. 2011 , 27, 1191-210 | | 61 |
| 547 | Pharmacological strategies for lowering LDL cholesterol: statins and beyond. 2011 , 8, 253-65 | | 75 |
| 546 | Use of a treatment optimization algorithm involving statin-ezetimibe combination aids in achievement of guideline-based low-density lipoprotein targets in patients with dyslipidemia at high vascular risk Guideline-based Undertaking to Improve Dyslipidemia Management in Canada (GUIDANCE). <i>Canadian Journal of Cardiology</i> , 2011 , 27, 138-45 | 3.8 | 5 |
| 545 | The effect of the change in the Framingham Risk Score calculator between the 2006 and 2009 Canadian lipid guidelines. <i>Canadian Journal of Cardiology</i> , 2011 , 27, 167-70 | 3.8 | 8 |
| 544 | Framing cardiovascular disease event risk prediction. <i>Canadian Journal of Cardiology</i> , 2011 , 27, 171-3 | 3.8 | 7 |
| 543 | Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group. <i>Canadian Journal of Cardiology</i> , 2011 , 27, e1-e33 | 3.8 | 116 |
| 542 | Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary). <i>Canadian Journal of Cardiology</i> , 2011 , 27, 124-31 | 3.8 | 41 |
| 541 | The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. <i>Canadian Journal of Cardiology</i> , 2011 , 27, 415-433.e1-2 | 3.8 | 93 |
| 540 | The challenges and benefits of cardiovascular risk assessment in clinical practice. <i>Canadian Journal of Cardiology</i> , 2011 , 27, 481-7 | 3.8 | 11 |
| 539 | Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. <i>Canadian Journal of Cardiology</i> , 2011 , 27, 635-62 | 3.8 | 135 |
| 538 | [Clinical applicability of the framingham 30-year risk score. Usefulness in cardiovascular risk stratification and the diagnosis of carotid atherosclerotic plaque]. 2011 , 64, 305-11 | | 12 |

| | | |
|-----|---|-----|
| 537 | [Comments on the ESC/EAS guidelines for the management of dyslipidaemias 2011. A report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology]. 2011 , 64, 1090-5 | 15 |
| 536 | HDL-C: role as a risk modifier. 2011 , 12, 267-70 | 71 |
| 535 | Clinical Applicability of the Framingham 30-Year Risk Score. Usefulness in Cardiovascular Risk Stratification and the Diagnosis of Carotid Atherosclerotic Plaque. 2011 , 64, 305-311 | |
| 534 | Comments on the 2011 ESC/EAS guidelines for the management of dyslipidemias. A report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology. 2011 , 64, 1090-1095 | |
| 533 | Coronary artery calcium score improves cardiovascular risk prediction in persons without indication for statin therapy. 2011 , 215, 229-36 | 33 |
| 532 | Do current criteria for 'healthy BMI' in adolescence warrant a re-think?. 2011 , 219, 30-2 | |
| 531 | Familial hypercholesterolaemia: a model of care for Australasia. 2011 , 12, 221-63 | 153 |
| 530 | CRP: star trekking the galaxy of risk markers. 2011 , 377, 441-2 | 5 |
| 529 | Global trends in body-mass index [Authors' reply. 2011 , 377, 1917-1918 | 8 |
| 528 | C-reactive protein in the Heart Protection Study. 2011 , 377, 1918; author reply 1918-9 | 3 |
| 527 | Novel inflammatory biomarkers in diseases: new hopes for diagnosis and therapy. 2011 , 10, 227-8 | |
| 526 | LIPRIMAR . FIFTEEN YEARS OF EVIDENCE. 2011 , 7, 231-240 | |
| 525 | Atherosclerotic Plaque Regression and Arterial Reverse Remodelling in Carotid and Femoral Arteries by Statin Use in Primary Prevention Setting: Ultrasound Findings. 2011 , | |
| 524 | Residual Vascular Risk in T2DM: The Next Frontier. 2011 , | |
| 523 | Prevalence, Predictors, and Impact of Low High-Density Lipoprotein Cholesterol on in-Hospital Outcomes Among Acute Coronary Syndrome Patients in the Middle East. 2011 , 5, 203-9 | 11 |
| 522 | Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. 2011 , 5, 325-80 | 162 |
| 521 | Effectiveness and tolerability of ezetimibe co-administered with statins versus statin dose-doubling in high-risk patients with persistent hyperlipidemia: The EZE(STAT)2 trial. 2011 , 7, 767-75 | 9 |
| 520 | Geographic variation in cardiovascular inflammation among healthy women in the Women's Health Study. 2011 , 6, e27468 | 6 |

| | | |
|-----|---|-----|
| 519 | Rheumatoid arthritis: is it a coronary heart disease equivalent?. 2011 , 26, 327-33 | 26 |
| 518 | Author Response. 2011 , 8, 430-431 | |
| 517 | Pharmacological treatment of obstructive sleep apnea. 2011 , 17, 1418-25 | 1 |
| 516 | Low-dose ASA Use for Primary Prevention of Cardiovascular Disease in Patients without Diabetes: When Should You Recommend it? A Case-Based Approach. 2011 , 144, 278-286.e1 | |
| 515 | The Canadian Hypertension Education Program (CHEP) 2011 Guidelines for Pharmacists. 2011 , 144, 295-304 | 7 |
| 514 | Reducing cardiovascular risk factors in patients with prediabetes. 2011 , 1, 423-438 | 1 |
| 513 | Controlling lipids after acute coronary syndromes: what is the best strategy?. 2011 , 6, 253-255 | |
| 512 | 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia. 2011 , 65, 82-101 | 14 |
| 511 | Incorporation of whole, ancient grains into a modern Asian Indian diet to reduce the burden of chronic disease. 2011 , 69, 479-88 | 47 |
| 510 | Innovative program to increase physical activity following an acute coronary syndrome: randomized controlled trial. 2011 , 85, e237-44 | 43 |
| 509 | Development and validation of the PAIR (Pharmacotherapy Assessment in Chronic Renal Disease) criteria to assess medication safety and use issues in patients with CKD. 2011 , 58, 527-35 | 24 |
| 508 | Nuevas herramientas en la estratificación del riesgo cardiovascular. 2011 , 11, 21-28 | |
| 507 | Comparison of high-density lipoprotein cholesterol to apolipoprotein A-I and A-II to predict coronary calcium and the effect of insulin resistance. 2011 , 107, 393-8 | 14 |
| 506 | Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, placebo-controlled, Randomized, double-blind, 12-week study with an open-label Extension [MARINE] trial). 2011 , 108, 682-90 | 254 |
| 505 | Miscellaneous non-inflammatory musculoskeletal conditions. Rare thesaurismosis and xanthomatosis. 2011 , 25, 683-701 | 10 |
| 504 | Multifactorial treatment for improvement of renal function and cardiovascular risk: an ATTEMPT for patients with metabolic syndrome and chronic kidney disease. 2011 , 27, 1669-72 | 3 |
| 503 | C-reactive protein, statins and the risk of vascular events: a better understanding. 2011 , 25, 545-9 | 6 |
| 502 | Lack of cardiovascular risk assessment in inflammatory arthritis and systemic lupus erythematosus patients at a tertiary care center. 2011 , 30, 1311-7 | 18 |

| | | |
|-----|---|-----|
| 501 | Statin therapy in metabolic syndrome and hypertension post-JUPITER: what is the value of CRP?. 2011 , 13, 31-42 | 29 |
| 500 | Are cardiovascular benefits in statin lipid effects dependent on baseline lipid levels?. 2011 , 13, 64-72 | 4 |
| 499 | Optimal medical therapy, lifestyle intervention, and secondary prevention strategies for cardiovascular event reduction in ischemic heart disease. 2011 , 13, 287-95 | 7 |
| 498 | Diabetes screening with hemoglobin A1c prior to a change in guideline recommendations: prevalence and patient characteristics. 2011 , 12, 91 | 8 |
| 497 | Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence. 2011 , 10, 20 | 44 |
| 496 | Lipid modification in the elderly using the combination of a statin and a cholesterol absorption inhibitor. 2011 , 12, 675-8 | 1 |
| 495 | Determining patient prognosis using computed tomography coronary angiography. 2011 , 8, 647-57 | 3 |
| 494 | The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus. 2011 , 6, 9-20 | 37 |
| 493 | Comprehensive cardiac rehabilitation for secondary prevention after transient ischemic attack or mild stroke: I: feasibility and risk factors. 2011 , 42, 3207-13 | 64 |
| 492 | Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men. 2011 , 52, 558-65 | 72 |
| 491 | Intestinal sterol transporters and cholesterol absorption inhibition. 2011 , 22, 467-78 | 20 |
| 490 | Dyslipidemia management. 2011 , 17, 1242-54 | |
| 489 | Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. 2011 , 183, E1189-202 | 84 |
| 488 | Lipid-lowering drug therapy in elderly patients. 2011 , 17, 877-93 | 18 |
| 487 | A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. 2011 , 4, 337-45 | 362 |
| 486 | C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians. 2011 , 123, 114-9 | 106 |
| 485 | New ESC/EAS Guidelines for the management of dyslipidaemias - any controversies behind the consensus?. 2011 , 18, 724-7 | 9 |
| 484 | Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk. 2011 , 183, E1180-8 | 25 |

| | | |
|-----|--|-----|
| 483 | Effectiveness of Ezetimibe in Reducing the Estimated Risk for Fatal Cardiovascular Events in Hypercholesterolaemic Patients with Inadequate Lipid Control While on Statin Monotherapy as Measured by the SCORE Model. 2011 , 2011, 597163 | 4 |
| 482 | Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians. 2011 , 2, 307-23 | 14 |
| 481 | Commentary: 'The end of clinical freedom': relevance in the era of evidence-based medicine. 2011 , 40, 855-8 | 3 |
| 480 | Harmonization of guidelines for the prevention and treatment of cardiovascular disease: the C-CHANGE Initiative. 2011 , 183, E1135-50 | 44 |
| 479 | Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial. 2011 , 306, 831-9 | 131 |
| 478 | Inflammatory markers in hyperlipidemia: from experimental models to clinical practice. 2011 , 17, 4132-46 | 35 |
| 477 | A classification of lipoprotein disorders: implications for clinical management. 2011 , 6, 327-338 | 7 |
| 476 | LDL-C or apoB as the best target for reducing coronary heart disease: should apoB be implemented into clinical practice?. 2011 , 6, 35-48 | 3 |
| 475 | High-sensitivity C-reactive protein, vascular imaging, and vulnerable plaque: more evidence to support trials of antiinflammatory therapy for cardiovascular risk reduction. 2011 , 4, 195-7 | 9 |
| 474 | The facts behind niacin. 2011 , 5, 227-40 | 16 |
| 473 | A tale of three labels: translating the JUPITER trial data into regulatory claims. 2011 , 8, 417-22 | 2 |
| 472 | Lipid parameters for measuring risk of cardiovascular disease. 2011 , 8, 197-206 | 144 |
| 471 | Postpartum exercise regardless of intensity improves chronic disease risk factors. 2011 , 43, 951-8 | 35 |
| 470 | A high carbohydrate diet induces the beneficial effect of the CC genotype of hepatic lipase C-514T polymorphism on the apoB100/apoAI ratio only in young Chinese males. 2012 , 72, 563-9 | 5 |
| 469 | Stroke and renal dysfunction: are we always conscious of this relationship?. 2012 , 18, 305-11 | 7 |
| 468 | A systematic review on the application of cardiovascular risk prediction models in pharmacoconomics, with a focus on primary prevention. 2012 , 19, 42-53 | 4 |
| 467 | What works and in whom? A simple, easily applied, evidence-based approach to guidelines for statin therapy. 2012 , 5, 592-3 | 7 |
| 466 | White adipose tissue apolipoprotein C-I secretion in relation to delayed plasma clearance of dietary fat in humans. 2012 , 32, 2785-93 | 15 |

| | | |
|-----|--|-----|
| 465 | Lipoprotein(a): more interesting than ever after 50 years. 2012 , 23, 133-40 | 89 |
| 464 | Cardiac rehabilitation participant with sickle cell trait and statin-related hepatotoxicity: a case report. 2012 , 32, 182-6 | 3 |
| 463 | Statins and noncardiac vascular disease. 2012 , 27, 392-7 | 17 |
| 462 | Assessment of management of cardiovascular risk factors in patients with thoracic aortic disease. 2012 , 17, 235-42 | 3 |
| 461 | Inclusion of stroke in cardiovascular risk prediction instruments: a statement for healthcare professionals from the American Heart Association/American Stroke Association. 2012 , 43, 1998-2027 | 105 |
| 460 | Low-density lipoprotein-lowering strategies: target versus maximalist versus population percentile. 2012 , 27, 405-11 | 15 |
| 459 | A pulse-based diet is effective for reducing total and LDL-cholesterol in older adults. 2012 , 108 Suppl 1, S103-10 | 60 |
| 458 | Lipid-related markers and cardiovascular disease prediction. 2012 , 307, 2499-506 | 271 |
| 457 | C-reactive protein, fibrinogen, and cardiovascular disease prediction. 2012 , 367, 1310-20 | 750 |
| 456 | Präventive Kardiologie. 2012 , 08, 321-334 | |
| 455 | Hyperlipoproteinämie - wie behandeln?. 2012 , 1, 60-65 | |
| 454 | Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia. 2012 , 10, 565-75 | 2 |
| 453 | Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. 2012 , 58, 183-9 | 110 |
| 452 | Stage of chronic kidney disease and severity of coronary heart disease manifestation. 2012 , 13, 457-60 | 10 |
| 451 | High-sensitive C-reactive protein: universal prognostic and causative biomarker in heart disease?. 2012 , 6, 19-34 | 34 |
| 450 | Pharmacogenetic determinants of statin-induced reductions in C-reactive protein. 2012 , 5, 58-65 | 27 |
| 449 | Thinking beyond traditional cardiovascular risk factors: the role of arterial stiffness in targeting residual risk. 2012 , 63, 9-11 | 14 |
| 448 | Laboratory approaches for predicting and managing the risk of cardiovascular disease: postanalytical opportunities of lipid and lipoprotein testing. 2012 , 50, 1169-81 | 10 |

| | | |
|-----|---|-----|
| 447 | A Randomized Trial Assessing the Effectiveness of Ezetimibe in South Asian Canadians with Coronary Artery Disease or Diabetes: The INFINITY Study. 2012 , 2012, 103728 | 6 |
| 446 | Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. 2012 , 126, 2283-92 | 222 |
| 445 | Rethinking dietary cholesterol. 2012 , 15, 117-21 | 36 |
| 444 | Dyslipidemia in patients with nonalcoholic fatty liver disease. 2012 , 32, 22-9 | 135 |
| 443 | Priorities for action to improve cardiovascular preventive care of patients with multimorbid conditions in primary care—a participatory action research project. 2012 , 29, 733-41 | 19 |
| 442 | Editorial: should chronic kidney disease be considered as a coronary heart disease equivalent?. 2012 , 10, 374-7 | 20 |
| 441 | National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. 2012 , 156, 591-5 | 146 |
| 440 | Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. 2012 , 225, 444-9 | 72 |
| 439 | Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. 2012 , 380, 1995-2006 | 276 |
| 438 | Assessment and Treatment of Cardiometabolic Risk in Adults at Risk for or with Type 2 Diabetes Mellitus. 2012 , 36, 320-326 | |
| 437 | Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. 2012 , 380, 2007-17 | 327 |
| 436 | Inhibition of cholesterol absorption: targeting the intestine. 2012 , 29, 3235-50 | 14 |
| 435 | Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled. 2012 , 44, 1731-44 | 30 |
| 434 | Prognostic implication of macrocytosis on adverse outcomes after coronary intervention. 2012 , 221, 148-53 | 25 |
| 433 | Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. 2012 , 223, 251-61 | 152 |
| 432 | A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: the Lipid Treatment Assessment Project 2. 2012 , 224, 150-3 | 29 |
| 431 | Intraindividual variability of C-reactive protein: the Multi-Ethnic Study of Atherosclerosis. 2012 , 224, 274-9 | 43 |
| 430 | Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies. 2012 , 6, 534-44 | 1 |

| | | |
|-----|---|---------|
| 429 | Low Levels of High-Density Lipoproteins Cholesterol Are Independently Associated With Acute Coronary Heart Disease in Patients Hospitalized for Chest Pain. 2012 , 65, 319-325 | 1 |
| 428 | High-sensitivity C-reactive protein as a biomarker of risk in coronary artery disease. 2012 , 31, 733-745 | 27 |
| 427 | The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. 2012 , 60, S1-49 | 476 |
| 426 | Parámetros lipídicos y objetivos terapéuticos. 2012 , 12, 12-18 | |
| 425 | Evidence for using alpha-lipoic acid in reducing lipoprotein and inflammatory related atherosclerotic risk. 2012 , 9, 116-27 | 10 |
| 424 | Niacin: another look at an underutilized lipid-lowering medication. 2012 , 8, 517-28 | 33 |
| 423 | Low levels of high-density lipoproteins cholesterol are independently associated with acute coronary heart disease in patients hospitalized for chest pain. 2012 , 65, 319-25 | 27 |
| 422 | Is it important to measure or reduce C-reactive protein in people at risk of cardiovascular disease?. 2012 , 33, 2258-64 | 12 |
| 421 | Secondary causes of dyslipidemia. 2012 , 110, 823-5 | 54 |
| 420 | Systematic review of guidelines on peripheral artery disease screening. 2012 , 125, 198-208.e3 | 46 |
| 419 | Lipid management in high risk coronary patients: how effective are we at secondary intervention?. 2012 , 21, 82-7 | 4 |
| 418 | A survey of physicians show a one-third reduction in harmful outcomes to be a clinically important difference for statin therapy. 2012 , 65, 954-61 | 2 |
| 417 | The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. 2012 , 1821, 405-15 | 135 |
| 416 | Quantification of concordance and discordance between apolipoprotein-B and the currently recommended non-HDL-cholesterol goals for cardiovascular risk assessment in patients with diabetes and hypertriglyceridemia. 2012 , 97, 51-6 | 6 |
| 415 | Perceptions of Canadian primary care physicians towards cardiovascular risk assessment and lipid management. <i>Canadian Journal of Cardiology</i> , 2012 , 28, 14-9 | 3.8 30 |
| 414 | How can we know what doctors know?. <i>Canadian Journal of Cardiology</i> , 2012 , 28, 11-3 | 3.8 1 |
| 413 | The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. <i>Canadian Journal of Cardiology</i> , 2012 , 28, 270-87 | 3.8 133 |
| 412 | Spray-dried pulse consumption does not affect cardiovascular disease risk or glycemic control in healthy males. 2012 , 48, 131-139 | 7 |

| | | | |
|-----|--|-----|-----|
| 411 | Coronary artery calcium findings in asymptomatic subjects with family history of premature coronary artery disease. 2012 , 12, 53 | | 1 |
| 410 | What is the role of advanced lipoprotein analysis in practice?. 2012 , 60, 2607-15 | | 16 |
| 409 | Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function in men with erectile dysfunction but naive to phosphodiesterase type 5 inhibitors. 2012 , 33, 1305-22 | | 11 |
| 408 | Therapeutic targeting of inflammation in atherosclerosis: we are getting closer. <i>Canadian Journal of Cardiology</i> , 2012 , 28, 619-22 | 3.8 | 8 |
| 407 | Statin use and the risk of incident diabetes mellitus: a review of the literature. <i>Canadian Journal of Cardiology</i> , 2012 , 28, 581-9 | 3.8 | 22 |
| 406 | Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. 2012 , 59, 2344-53 | | 415 |
| 405 | Lipid testing in patients with rheumatoid arthritis and key cardiovascular-related comorbidities: a medicare analysis. 2012 , 42, 9-16 | | 32 |
| 404 | Management of cardiovascular disease risk factors in individuals with chronic spinal cord injury: an evidence-based review. 2012 , 29, 1999-2012 | | 38 |
| 403 | [High-sensitivity C-reactive protein as a biomarker of risk in coronary artery disease]. 2012 , 31, 733-45 | | 35 |
| 402 | Update on guidelines for management of hypercholesterolemia. 2012 , 10, 1239-49 | | 3 |
| 401 | Comparison of the Framingham and Reynolds Risk scores for global cardiovascular risk prediction in the multiethnic Women's Health Initiative. 2012 , 125, 1748-56, S1-11 | | 168 |
| 400 | Association between salivary pH and metabolic syndrome in women: a cross-sectional study. 2012 , 12, 40 | | 8 |
| 399 | Women up, men down: the clinical impact of replacing the Framingham Risk Score with the Reynolds Risk Score in the United States population. 2012 , 7, e44347 | | 14 |
| 398 | The impact of abdominal obesity status on cardiovascular response to the mediterranean diet. 2012 , 2012, 969124 | | 9 |
| 397 | Cardiac work-up protocol for liver transplant candidates: experience from a single liver transplant centre. 2012 , 26, 806-10 | | 4 |
| 396 | Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines. 2012 , 65, 125-45 | | 29 |
| 395 | Population-based study of high plasma C-reactive protein concentrations among the Inuit of Nunavik. 2012 , 71, | | 13 |
| 394 | Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. 2012 , 46, 549-57 | | 86 |

| | | |
|-----|--|----|
| 393 | Coronary risk assessment in patients with HIV infection: why bother?. 2012 , 28, 989-92 | |
| 392 | Prevention of heart failure in the elderly: when, where and how to begin?. 2012 , 17, 531-44 | 14 |
| 391 | The Role of Statin Therapy for Primary Prevention: What is the Evidence?. 2012 , 14, 167 | 4 |
| 390 | The Role of Exercise Interventions in Reducing the Risk for Cardiometabolic Disease in Cancer Survivors. 2012 , 6, 313-322 | 1 |
| 389 | Managing cardiovascular risk in patients with chronic inflammatory diseases. 2012 , 31, 585-94 | 16 |
| 388 | Added value of CAC in risk stratification for cardiovascular events: a systematic review. 2012 , 42, 110-6 | 31 |
| 387 | Frequency of intensive statin therapy in patients with acute coronary syndrome admitted to a tertiary care center. 2012 , 109, 1-5 | 7 |
| 386 | Temporal patterns of lipid testing and statin therapy in acute coronary syndrome patients (from the Canadian GRACE Experience). 2012 , 109, 1418-24 | 9 |
| 385 | Waiting for the National Cholesterol Education Program Adult Treatment Panel IV Guidelines, and in the meantime, some challenges and recommendations. 2012 , 110, 307-13 | 32 |
| 384 | Management of cardiovascular risk: the importance of meeting lipid targets. 2012 , 110, 3A-14A | 56 |
| 383 | Impact of kinins in the treatment of cardiovascular diseases. 2012 , 135, 94-111 | 62 |
| 382 | Utility of non-high-density lipoprotein cholesterol in assessing incident type 2 diabetes risk. 2012 , 14, 821-5 | 19 |
| 381 | Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study. 2012 , 11, 18 | 9 |
| 380 | Relationships of different blood pressure categories to indices of inflammation and platelet activity in sustained hypertensive patients with uncontrolled office blood pressure. 2013 , 30, 973-80 | 15 |
| 379 | A three stage ontology-driven solution to provide personalized care to chronic patients at home. 2013 , 46, 516-29 | 56 |
| 378 | CLSI-based transference of the CALIPER database of pediatric reference intervals from Abbott to Beckman, Ortho, Roche and Siemens Clinical Chemistry Assays: direct validation using reference samples from the CALIPER cohort. 2013 , 46, 1197-219 | 71 |
| 377 | The impact of handgrip exercise duty cycle on brachial artery flow-mediated dilation. 2013 , 113, 1849-58 | 13 |
| 376 | Nutrient- and non-nutrient-based natural health product (NHP) use in adults with mood disorders: prevalence, characteristics and potential for exposure to adverse events. 2013 , 13, 80 | 7 |

| | | | |
|-----|--|-----|-----|
| 375 | Discriminant ratio and biometrical equivalence of measured vs. calculated apolipoprotein B100 in patients with T2DM. 2013 , 12, 39 | | 6 |
| 374 | Statins in cardiometabolic disease: what makes pitavastatin different?. 2013 , 12 Suppl 1, S1 | | 13 |
| 373 | Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy. 2013 , 15, 397 | | 25 |
| 372 | Lipoprotein and Lipid Metabolism. 2013 , 1-33 | | 2 |
| 371 | High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?. 2013 , 62, 397-408 | | 316 |
| 370 | HDL-C: clinical equipoise and vascular endothelial function. 2013 , 11, 343-53 | | 16 |
| 369 | C-reactive protein and atherothrombosis: Cause or effect?. 2013 , 27, 23-9 | | 38 |
| 368 | Low prevalence of type 2 diabetes mellitus among patients with high levels of high-density lipoprotein cholesterol. 2013 , 7, 194-8 | | 7 |
| 367 | Low-glycaemic index diets in the management of blood lipids: a systematic review and meta-analysis. 2013 , 30, 485-91 | | 25 |
| 366 | Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. 2013 , 166, 199-207.e15 | | 276 |
| 365 | Management of risk factors among ambulatory patients at high cardiovascular risk in Canada: a follow-up study. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 1586-92 | 3.8 | 4 |
| 364 | The CHANGE program: comparing an interactive vs. prescriptive approach to self-management among university students with obesity. 2013 , 37, 4-11 | | 22 |
| 363 | Advances in cardiac SPECT and PET imaging: overcoming the challenges to reduce radiation exposure and improve accuracy. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 275-84 | 3.8 | 17 |
| 362 | Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. 2013 , 310, 2061-8 | | 342 |
| 361 | The toe-brachial index in the diagnosis of peripheral arterial disease. 2013 , 58, 231-8 | | 139 |
| 360 | Computationally estimated apolipoproteins B and A1 in predicting cardiovascular risk. 2013 , 226, 245-51 | | 17 |
| 359 | A retrospective study of the Framingham cardiovascular risk scores in a liver transplant population. 2013 , 45, 308-14 | | 3 |
| 358 | Pitavastatin in cardiometabolic disease: therapeutic profile. 2013 , 12 Suppl 1, S2 | | 16 |

| | | | |
|-----|--|-----|----|
| 357 | Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects. 2013 , 12, 103 | | 3 |
| 356 | Prevalence of cardiovascular risk factors and socioeconomic level among public-sector workers in Angola. 2013 , 13, 732 | | 31 |
| 355 | Feedback GAP: pragmatic, cluster-randomized trial of goal setting and action plans to increase the effectiveness of audit and feedback interventions in primary care. 2013 , 8, 142 | | 24 |
| 354 | Type 2 diabetes mellitus management in Canada: is it improving?. 2013 , 37, 82-9 | | 92 |
| 353 | Evidence of enhanced systemic inflammation in stable kidney transplant recipients with low Framingham risk scores. 2013 , 27, E391-9 | | 11 |
| 352 | Effect of exercise training combined with isoflavone supplementation on bone and lipids in postmenopausal women: a randomized clinical trial. 2013 , 28, 780-93 | | 50 |
| 351 | Association of lipoprotein levels with mortality in subjects aged 50 + without previous diabetes or cardiovascular disease: a population-based register study. 2013 , 31, 172-80 | | 32 |
| 350 | Genetics 100 for cardiologists: basics of genome-wide association studies. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 10-7 | 3.8 | 27 |
| 349 | Biomarkers. Screening for C-reactive protein in CVD prediction. 2013 , 10, 12-4 | | 7 |
| 348 | The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome. 2013 , 15, 513-22 | | 4 |
| 347 | Prediction of Global Cardiovascular Risk in Hypertension. 2013 , 144-150 | | |
| 346 | Hypertriglyceridemia is associated with insulin levels in adult cystic fibrosis patients. 2013 , 12, 271-6 | | 22 |
| 345 | Length of initial prescription at hospital discharge and long-term medication adherence for elderly patients with coronary artery disease: a population-level study. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 1408-14 | 3.8 | 22 |
| 344 | Non-high-density lipoprotein cholesterol, guideline targets, and population percentiles for secondary prevention in 1.3 million adults: the VLDL-2 study (very large database of lipids). 2013 , 62, 1960-1965 | | 49 |
| 343 | Lifetime risk prediction in cardiovascular prevention: wave of the future?. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 142-3 | 3.8 | 1 |
| 342 | Pharmacologic Therapy for Obstructive Sleep Apnea. 2013 , 8, 527-542 | | 1 |
| 341 | Diagnostic implication of change in b-type natriuretic peptide (BNP) for prediction of subsequent target lesion revascularization following sirolimus-eluting stent deployment. 2013 , 168, 1429-34 | | 2 |
| 340 | 10-Year Framingham risk in patients with retinal vein occlusion: a systematic review and meta-analysis. 2013 , 48, 40-45.e1 | | 17 |

| | | | |
|-----|---|-----|-----|
| 339 | Understanding palliative care on the heart failure care team: an innovative research methodology. 2013 , 45, 901-11 | | 25 |
| 338 | Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. 2013 , 62, 732-9 | | 217 |
| 337 | Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting. 2013 , 7, 399-407 | | 18 |
| 336 | Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia. 2013 , 229, 415-22 | | 11 |
| 335 | Clinical equivalence of proprietary and generic atorvastatin in lipid clinic patients. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 418-22 | 3.8 | 7 |
| 334 | Efficacy and plasma drug concentrations with nondaily dosing of rosuvastatin. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 915-9 | 3.8 | 9 |
| 333 | Identification and management of patients at elevated cardiometabolic risk in canadian primary care: how well are we doing?. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 960-8 | 3.8 | 15 |
| 332 | Does it make sense to combine statins with other lipid-altering agents following AIM-HIGH, SHARP and ACCORD?. 2013 , 15, 290 | | 2 |
| 331 | Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?. 2013 , 15, 295 | | 61 |
| 330 | The evolution or revolution of statin therapy in primary prevention: where do we go from here?. 2013 , 15, 298 | | 4 |
| 329 | Establishing cut-off values for apolipoprotein B and non-HDL-C according to LDL-C values in a South European population. 2013 , 67, 81-8 | | 8 |
| 328 | Statins for the primary prevention of cardiovascular disease. 2013 , CD004816 | | 490 |
| 327 | Discordance between non-HDL-cholesterol and LDL-particle measurements: results from the Multi-Ethnic Study of Atherosclerosis. 2013 , 229, 517-23 | | 28 |
| 326 | Effect of the SORT1 low-density lipoprotein cholesterol locus is sex-specific in a fit, Canadian young-adult population. 2013 , 38, 188-93 | | 8 |
| 325 | 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 151-67 | 3.8 | 545 |
| 324 | Lipids in Women. 2013 , 965-974 | | |
| 323 | Cardiovascular risk and atherosclerosis prevention. 2013 , 22, 16-8 | | 42 |
| 322 | A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease. 2013 , 10, 277-86 | | 16 |

| | | |
|-----|---|-----|
| 321 | Cardiovascular Disease Risk Prediction - Integration into Clinical Practice. 2013 , 7, 346-353 | 2 |
| 320 | Rhetoric and argumentation: how clinical practice guidelines think. 2013 , 19, 433-41 | 10 |
| 319 | Omega-3 Fatty Acids in Prevention of Cardiovascular Disease in Humans: Chemistry, Dyslipidemia. 2013 , 465-489 | 1 |
| 318 | Omega-3 Fatty Acids in Prevention of Cardiovascular Disease in Humans. 2013 , 1-28 | |
| 317 | C-reactive protein level and the incidence of eligibility for statin therapy: the multi-ethnic study of atherosclerosis. 2013 , 36, 15-20 | 3 |
| 316 | Longitudinal trends in nutritional status and the relation between lung function and BMI in cystic fibrosis: a population-based cohort study. 2013 , 97, 872-7 | 87 |
| 315 | Adding a life-course perspective to cardiovascular-risk communication. 2013 , 10, 111-5 | 33 |
| 314 | C-reactive protein and cholesterol are equally strong predictors of cardiovascular risk and both are important for quality clinical care. 2013 , 34, 1258-61 | 30 |
| 313 | Collaborative Cardiovascular Risk Reduction in Primary Care II (CCARP II): Implementation of a systematic case-finding process for patients with uncontrolled risk factors. 2013 , 146, 284-92 | 2 |
| 312 | Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. 2013 , 6, 400-8 | 124 |
| 311 | Discordance between Framingham Risk Score and atherosclerotic plaque burden. 2013 , 34, 1075-82 | 41 |
| 310 | Diagnosis and treatment of familial hypercholesterolaemia. 2013 , 34, 962-71 | 187 |
| 309 | Examining the risk of cardiovascular disease in patients with psoriasis: a critical review. 2013 , 17, 89-105 | 6 |
| 308 | Putting cardiovascular risk into perspective: A view from a pharmacist patient. 2013 , 146, 97-100 | |
| 307 | Beyond LDL cholesterol in assessing cardiovascular risk: apo B or LDL-P?. 2013 , 59, 723-5 | 15 |
| 306 | Assessment of high cardiovascular risk profiles for the clinician. 2013 , 64, 333-5 | |
| 305 | Low density lipoprotein delays clearance of triglyceride-rich lipoprotein by human subcutaneous adipose tissue. 2013 , 54, 1466-76 | 19 |
| 304 | Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey. 2013 , 185, E417-23 | 195 |

| | | |
|-----|---|----|
| 303 | The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups. 2013 , 8, 13-41 | 21 |
| 302 | Targeted quantitation of CVD-linked plasma proteins for biomarker verification and validation. 2013 , 10, 567-78 | 7 |
| 301 | Very large database of lipids: rationale and design. 2013 , 36, 641-8 | 33 |
| 300 | Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: from the look AHEAD study. 2013 , 21, 944-50 | 42 |
| 299 | Complementary prediction of cardiovascular events by estimated apo- and lipoprotein concentrations in the working age population. The Health 2000 Study. 2013 , 45, 141-8 | 4 |
| 298 | A comparison of the assessment and management of cardiometabolic risk in patients with and without type 2 diabetes mellitus in Canadian primary care. 2013 , 15, 1093-100 | 11 |
| 297 | Trends in C-reactive protein levels in US adults from 1999 to 2010. 2013 , 177, 1430-42 | 30 |
| 296 | Exercise in a healthy heart program: a cohort study. 2013 , 7, 145-51 | 1 |
| 295 | Dietary management of the metabolic syndrome - one size fits all?. 2013 , 72, 310-6 | 4 |
| 294 | Hyperuricaemia: more than just a cause of gout?. 2013 , 14, 397-402 | 58 |
| 293 | Dyslipidemia prevalence, treatment, control, and awareness in the Canadian Health Measures Survey. 2013 , 104, e252-7 | 36 |
| 292 | Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin. 2013 , 9, 273-82 | 5 |
| 291 | Vascular protection in patients with diabetes admitted for vascular surgery in a canadian tertiary care hospital: pilot study. 2013 , 66, 227-32 | 4 |
| 290 | Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies. 2013 , 19, 3161-72 | 59 |
| 289 | Polymorphisms in Fatty Acid Desaturase (FADS) Gene Cluster: Effects on Glycemic Controls Following an Omega-3 Polyunsaturated Fatty Acids (PUFA) Supplementation. 2013 , 4, 485-98 | 19 |
| 288 | Subclinical hypothyroidism and vascular risk: an update. 2013 , 12, 495-506 | 21 |
| 287 | Disparities in receipt of screening tests for cancer, diabetes and high cholesterol in Ontario, Canada: a population-based study using area-based methods. 2013 , 104, e284-90 | 46 |
| 286 | Progesterone therapy, endothelial function and cardiovascular risk factors: a 3-month randomized, placebo-controlled trial in healthy early postmenopausal women. 2014 , 9, e84698 | 27 |

| | | |
|-----|--|----|
| 285 | Unmet needs for cardiovascular care in Indonesia. 2014 , 9, e105831 | 13 |
| 284 | Dyslipidemia in women: etiology and management. 2014 , 6, 185-94 | 35 |
| 283 | Effects of extended-release niacin/laropirant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia. 2014 , 10, 279-90 | 8 |
| 282 | Impact of an integrated obesity management system on patient's care - research protocol. 2014 , 1, 19 | 9 |
| 281 | Independent external validation of cardiovascular disease mortality in women utilising Framingham and SCORE risk models: a mortality follow-up study. 2014 , 14, 118 | 23 |
| 280 | Impact of the traditional Mediterranean diet on the Framingham risk score and the metabolic syndrome according to sex. 2014 , 12, 95-101 | 1 |
| 279 | Effect of an intervention to improve the cardiovascular health of family members of patients with coronary artery disease: a randomized trial. 2014 , 186, 23-30 | 21 |
| 278 | Adipocytokines, metabolic syndrome, and exercise. 2014 , 2014, 597162 | 7 |
| 277 | Anthropometric measurements of general and central obesity and the prediction of cardiovascular disease risk in women: a cross-sectional study. 2014 , 4, e004138 | 63 |
| 276 | Ethnicity and the association between anthropometric indices of obesity and cardiovascular risk in women: a cross-sectional study. 2014 , 4, e004702 | 19 |
| 275 | Impact of the JUPITER trial on statin prescribing for primary prevention. 2014 , 34, 9-18 | 4 |
| 274 | Measurement of low-density lipoprotein cholesterol in assessment and management of cardiovascular disease risk. 2014 , 96, 20-2 | 6 |
| 273 | The relationship between inflammatory and oxidative stress biomarkers, atherosclerosis and rheumatic diseases. 2014 , 20, 585-600 | 22 |
| 272 | Evaluation of preventive cardiovascular pharmacotherapy after coronary artery bypass graft surgery. 2014 , 34, 464-72 | 7 |
| 271 | Consumer attitudes and understanding of cholesterol-lowering claims on food: randomize mock-package experiments with plant sterol and oat fibre claims. 2014 , 68, 946-52 | 29 |
| 270 | Should we expand the concept of coronary heart disease equivalents?. 2014 , 29, 389-95 | 26 |
| 269 | Urinary Metabolomics on the Biochemical Profiles in Diet-Induced Hyperlipidemia Rat Using Ultraperformance Liquid Chromatography Coupled with Quadrupole Time-of-Flight SYNAPT High-Definition Mass Spectrometry. 2014 , 2014, 184162 | 27 |
| 268 | Prevalence, awareness, and management of CKD and cardiovascular risk factors in publicly funded health care. 2014 , 9, 713-9 | 28 |

| | | | |
|-----|--|-----|-----|
| 267 | Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials. 2014 , 8, 441-7 | | 15 |
| 266 | Sex- and gender-related risk factor burden in patients with premature acute coronary syndrome. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 109-17 | 3.8 | 43 |
| 265 | Impact of the ENHANCE trial on the use of ezetimibe in the United States and Canada. 2014 , 167, 683-9 | | 14 |
| 264 | Implementing New Guidelines: Changing Paradigms for the Prevention of Cardiovascular Events. 2014 , 10, 293-301 | | 1 |
| 263 | Chronic kidney disease, lipids and apolipoproteins, and coronary heart disease: the ARIC study. 2014 , 234, 42-6 | | 33 |
| 262 | The "New Deadly Quartet" for cardiovascular disease in the 21st century: obesity, metabolic syndrome, inflammation and climate change: how does statin therapy fit into this equation?. 2014 , 16, 380 | | 11 |
| 261 | How low an LDL-C should we go with statin therapy?. 2014 , 16, 388 | | 4 |
| 260 | Laboratory Assessment of Lipoproteins in Diabetes. 2014 , 1-10 | | 1 |
| 259 | 2013 ACC/AHA cholesterol treatment guideline: what was done well and what could be done better. 2014 , 63, 2674-8 | | 47 |
| 258 | Characteristics and evidence-based management of stable coronary artery disease patients in Canada compared with the rest of the world: insights from the CLARIFY registry. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 132-7 | 3.8 | 6 |
| 257 | Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. 2014 , 383, 60-68 | | 395 |
| 256 | Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis. 2014 , 129, 77-86 | | 172 |
| 255 | Metabolomics reveals the sex-specific effects of the SORT1 low-density lipoprotein cholesterol locus in healthy young adults. 2014 , 13, 5063-70 | | 8 |
| 254 | Screening for peripheral arterial disease. 2014 , CD010835 | | 13 |
| 253 | Impact of drug policy on regional trends in ezetimibe use. 2014 , 7, 589-96 | | 7 |
| 252 | The Risk-Benefit Paradigm vs the Causal Exposure Paradigm: LDL as a primary cause of vascular disease. 2014 , 8, 594-605 | | 11 |
| 251 | [LDL cholesterol control in patients with very high cardiovascular risk. A simplified algorithm for achieving LDL cholesterol goals "in two steps"]. 2014 , 26, 242-52 | | |
| 250 | Pharmacogenetics in cardiovascular disease: the challenge of moving from promise to realization: concepts discussed at the Canadian Network and Centre for Trials Internationally Network Conference (CANNeCTIN), June 2009. 2014 , 37, 48-56 | | 10 |

| | | | |
|-----|---|-----|------|
| 249 | Carotid intima-media thickness in patients with inflammatory bowel disease: a systematic review. 2014 , 65, 284-93 | | 20 |
| 248 | 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 , 129, S49-73 | | 2093 |
| 247 | Genetic counseling in direct-to-consumer exome sequencing: a case report. 2014 , 23, 742-53 | | 4 |
| 246 | Mapping the expanded often inappropriate use of the Framingham Risk Score in the medical literature. 2014 , 67, 571-7 | | 7 |
| 245 | Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III). 2014 , 130, 546-53 | | 94 |
| 244 | Rationale and design of a randomized clinical study to investigate the effect of ezetimibe, a cholesterol absorption inhibitor, on the regression of intracoronary plaque evaluated by non-obstructive angiography and ultrasound: The ZIPANGU study. 2014 , 64, 501-7 | | 8 |
| 243 | 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 , 63, 2935-2959 | | 1625 |
| 242 | Quality of diabetes care in the Canadian forces. 2014 , 38, 11-6 | | 1 |
| 241 | Water dispersible plant sterol formulation shows improved effect on lipid profile compared to plant sterol esters. 2014 , 6, 280-289 | | 16 |
| 240 | Use and misuse of ezetimibe: analysis of use and cost in Saskatchewan, a Canadian jurisdiction with broad access. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 237-43 | 3.8 | 3 |
| 239 | The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of dyslipidemia: mind the gaps!. 2014 , 30, 1701-5 | | 6 |
| 238 | Adverse event management of mTOR inhibitors during treatment of hormone receptor-positive advanced breast cancer: considerations for oncologists. 2014 , 14, 297-308 | | 20 |
| 237 | Epidemiology, traditional and novel risk factors in coronary artery disease. 2014 , 32, 323-32 | | 38 |
| 236 | N-of-1 (single-patient) trials for statin-related myalgia. 2014 , 160, 301-10 | | 76 |
| 235 | Managing Menopause Chapter 1 Assessment and Risk Management of Menopausal Women. 2014 , 36, S6-S15 | | 1 |
| 234 | The hypertriglyceridemic-waist phenotype is associated with the Framingham risk score and subclinical atherosclerosis in Canadian Cree. 2015 , 25, 1050-5 | | 7 |
| 233 | Erectile dysfunction and coronary heart disease. 2015 , 30, 416-21 | | 26 |
| 232 | Impact of corpulence parameters and haemoglobin A1c on metabolic control in type 2 diabetic patients: comparison of apolipoprotein B/A-I ratio with fasting and postprandial conventional lipid ratios. 2015 , 10, 27400 | | 4 |

| | | |
|-----|---|----|
| 231 | Is nutritional labeling associated with individual health? The effects of labeling-based awareness on dyslipidemia risk in a South Korean population. 2016 , 15, 81 | 6 |
| 230 | Targeted study to evaluate the cardiovascular risk factor status among patients and efficacy of statins in attaining goal lipid levels in a regional hospital in Sultanate of Oman. 2015 , 23, 371-6 | 1 |
| 229 | Low density lipoprotein cholesterol control status among Canadians at risk for cardiovascular disease: findings from the Canadian Primary Care Sentinel Surveillance Network Database. 2015 , 14, 60 | 8 |
| 228 | Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk. 2015 , 14, 103 | 8 |
| 227 | Small-area variation in screening for cancer, glucose and cholesterol in Ontario: a cross-sectional study. 2015 , 3, E373-81 | 14 |
| 226 | Single and mixed dyslipidaemia in Canadian primary care settings: findings from the Canadian primary care sentinel surveillance network database. 2015 , 5, e007954 | 10 |
| 225 | Kidney Paired Donation Protocol for Participating Donors 2014. 2015 , 99, S1-S88 | 24 |
| 224 | Adaptive practices in heart failure care teams: implications for patient-centered care in the context of complexity. 2015 , 8, 365-76 | 16 |
| 223 | Severe multivessel coronary artery disease and high-sensitive troponin T. 2015 , 12, 139-44 | 1 |
| 222 | Consolidated and emerging inflammatory markers in coronary artery disease. 2015 , 5, 21-32 | 43 |
| 221 | The FADOI (Federation of Associations of Hospital Doctors on Internal Medicine) position paper on cardiovascular prevention in the higher risk complex patients. 2015 , 9, 387 | |
| 220 | Does the Prevalence of Dyslipidemias Differ between Newfoundland and the Rest of Canada? Findings from the Electronic Medical Records of the Canadian Primary Care Sentinel Surveillance Network. 2015 , 2, 1 | 16 |
| 219 | Framingham ten-year general cardiovascular disease risk: agreement between BMI-based and cholesterol-based estimates in a South Asian convenience sample. 2015 , 10, e0119183 | 9 |
| 218 | A Comparison of Accelerometer Cut-Points among Individuals with Coronary Artery Disease. 2015 , 10, e0137759 | 20 |
| 217 | Correlation Between Dietary Fat Intake and Atherogenic Indices in Normal, Overweight and Obese Adults with or Without Type 2 Diabetes. 2015 , 22, 347-360 | 5 |
| 216 | Six-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality. 2015 , 170, 380-9 | 69 |
| 215 | Lipoproteins and Cardiovascular Disease Risk. 2015 , 57-65 | |
| 214 | Prediction of ventricular arrhythmia events in ischemic heart disease patients with implantable cardioverter-defibrillators. 2015 , 26, 240 | 2 |

| | | |
|-----|---|-----|
| 213 | Hydrogen sulfide reduces serum triglyceride by activating liver autophagy via the AMPK-mTOR pathway. 2015 , 309, E925-35 | 79 |
| 212 | Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. 2015 , 74, 668-74 | 174 |
| 211 | Docosahexaenoic acid-enriched canola oil increases adiponectin concentrations: a randomized crossover controlled intervention trial. 2015 , 25, 52-9 | 21 |
| 210 | Interaction between periodontal disease and atherosclerotic vascular disease--Fact or fiction?. 2015 , 241, 555-60 | 43 |
| 209 | Contemporary Cardiovascular Concerns after Spinal Cord Injury: Mechanisms, Maladaptations, and Management. 2015 , 32, 1927-42 | 95 |
| 208 | The Risk GP Model: the standard model of prediction in medicine. 2015 , 54, 49-61 | 21 |
| 207 | Cardiovascular Biomarker Assessment Across Glycemic Status. 2015 , 245-268 | 0 |
| 206 | Successful reintroduction of statin therapy after statin-associated rhabdomyolysis. 2015 , 9, 594-6 | 5 |
| 205 | Primary prevention of cardiovascular disease: global cardiovascular risk assessment and management in clinical practice. 2015 , 1, 31-36 | 5 |
| 204 | Predictors of poor coronary collateral development in patients with stable coronary artery disease: neutrophil-to-lymphocyte ratio and platelets. 2015 , 15, 218-23 | 11 |
| 203 | Prevention of cardiovascular disease in rheumatoid arthritis. 2015 , 14, 952-69 | 57 |
| 202 | Prognostic and therapeutic implications of statin and aspirin therapy in individuals with nonobstructive coronary artery disease: results from the CONFIRM (COronary CT Angiography EvaluationN For Clinical Outcomes: An InteRnational Multicenter registry) registry. 2015 , 35, 981-9 | 101 |
| 201 | Possible mechanisms of C-reactive protein mediated acute myocardial infarction. 2015 , 760, 72-80 | 27 |
| 200 | Associations of total and abdominal adiposity with risk marker patterns in children at high-risk for cardiovascular disease. 2015 , 2, 15 | 8 |
| 199 | Sex differences in the impact of the Mediterranean diet on systemic inflammation. 2015 , 14, 46 | 22 |
| 198 | High-Sensitivity C-Reactive Protein and Statin Initiation. 2015 , 66, 503-7 | |
| 197 | Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: a European cross-sectional study. 2015 , 240, 90-7 | 31 |
| 196 | Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia. 2015 , 9, 201-9 | 21 |

| | | |
|-----|--|--------|
| 195 | New Approaches in Detection and Treatment of Familial Hypercholesterolemia. 2015 , 17, 109 | 20 |
| 194 | Canadian Stroke Best Practice Recommendations: secondary prevention of stroke guidelines, update 2014. 2015 , 10, 282-91 | 79 |
| 193 | Metabolic abnormalities among people diagnosed with schizophrenia: a literature review and implications for mental health nurses. 2015 , 22, 157-70 | 23 |
| 192 | A randomized trial of the effects of ezetimibe on the absorption of omega-3 fatty acids in cardiac disease patients: A pilot study. 2015 , 10, e155-e159 | 4 |
| 191 | The new dyslipidemia guidelines: what is the debate?. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 605-12 | 3.8 32 |
| 190 | Effect of purified eicosapentaenoic acid on red cell distribution width in patients with ischemic heart disease. 2015 , 30, 587-94 | 6 |
| 189 | Pharmacological treatment of hypertension and hyperlipidemia in Izhevsk, Russia. 2016 , 16, 122 | 7 |
| 188 | Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes. 2016 , 15, 116 | 3 |
| 187 | A New GUI Device for Monitoring Cardiovascular Status. 2016 , | |
| 186 | Nutritional management of hyperapoB. 2016 , 29, 202-233 | 16 |
| 185 | Comprehensive Analysis of Established Dyslipidemia-Associated Loci in the Diabetes Prevention Program. 2016 , 9, 495-503 | 3 |
| 184 | Management of homozygous familial hypercholesterolemia in real-world clinical practice: A report of 7 Italian patients treated in Rome with lomitapide and lipoprotein apheresis. 2016 , 10, 782-789 | 22 |
| 183 | 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). 2016 , 37, 2315-2381 | 3919 |
| 182 | Clinical relevance of high sensitivity C-reactive protein in cardiology. 2016 , 52, 1-10 | 42 |
| 181 | The Effectiveness of Pharmacist Interventions on Cardiovascular Risk: The Multicenter Randomized Controlled Rx EACH Trial. 2016 , 67, 2846-54 | 107 |
| 180 | Primary Prevention of Cardiovascular Disease in Older Adults. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1074-81 | 3.8 14 |
| 179 | Variations in HDL-carried miR-223 and miR-135a concentrations after consumption of dietary trans fat are associated with changes in blood lipid and inflammatory markers in healthy men - an exploratory study. 2016 , 11, 438-48 | 21 |
| 178 | Non-alcoholic fatty liver disease and dyslipidemia: An update. 2016 , 65, 1109-23 | 212 |

| | | |
|-----|--|-----------------|
| 177 | Longitudinal treatment patterns among US patients with atherosclerotic cardiovascular disease or familial hypercholesterolemia initiating lipid-lowering pharmacotherapy. 2016 , 10, 1470-1480.e3 | 1 |
| 176 | Guía ESC 2016 sobre prevención de la enfermedad cardiovascular en la práctica clínica. 2016 , 69, 939.e1-939.e87 | 10 |
| 175 | A randomized trial of a community-based approach to dyslipidemia management: Pharmacist prescribing to achieve cholesterol targets (RxACT Study). 2016 , 149, 283-292 | 36 |
| 174 | 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular | 34 ¹ |
| 173 | Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation. 2016 , 291, 16659-71 | 23 |
| 172 | WAT apoC-I secretion: role in delayed chylomicron clearance in vivo and ex vivo in WAT in obese subjects. 2016 , 57, 1074-85 | 6 |
| 171 | High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome: Subanalysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events Trial. 2016 , 47, 2025-30 | 41 |
| 170 | Do Rural Patients in Canada Underutilize Preventive Care for Myocardial Infarction?. 2016 , 32, 345-352 | 4 |
| 169 | 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular | 445 |
| 168 | Prevention & Rehabilitation (FACPR). 2016 , 23, NP1-NP96 Epidemiology, Traditional and Novel Risk Factors in Coronary Artery Disease. 2016 , 12, 1-10 | 37 |
| 167 | Hypolipidemic Effects of Alkaloids from Rhizoma Coptidis in Diet-Induced Hyperlipidemic Hamsters. 2016 , 82, 690-7 | 35 |
| 166 | Renal function trajectory over time and adverse clinical outcomes. 2016 , 20, 379-93 | 8 |
| 165 | Serum neutrophil gelatinase-associated lipocalin concentration reflects severity of coronary artery disease in patients without heart failure and chronic kidney disease. 2016 , 31, 1595-602 | 11 |
| 164 | The impact of red and processed meat consumption on cardiovascular disease risk in women. 2016 , 32, 349-54 | 28 |
| 163 | Morphological Changes in the Carotid Artery Intima after Gastric Bypass for Morbid Obesity. 2017 , 27, 357-363 | 17 |
| 162 | Lipid and lipoprotein abnormalities in acute lymphoblastic leukemia survivors. 2017 , 58, 982-993 | 31 |
| 161 | Lipid-lowering treatment modifications among patients with hyperlipidemia and a prior cardiovascular event: a US retrospective cohort study. 2017 , 33, 869-876 | 5 |
| 160 | Dietary carbohydrate and fat intakes are differentially associated with lipid abnormalities in Korean adults. 2017 , 11, 338-347.e3 | 19 |

| | | |
|-----|--|----|
| 159 | Identification of Dyslipidemic Patients Attending Primary Care Clinics Using Electronic Medical Record (EMR) Data from the Canadian Primary Care Sentinel Surveillance Network (CPCSSN) Database. 2017 , 41, 45 | 10 |
| 158 | Stent liberadores de medicamento en enfermedad coronaria prematura en jóvenes con hipercolesterolemia familiar homocigota y trasplante hepático previo. 2017 , 24, 351-360 | |
| 157 | High Dose Supplementation of Vitamin D Affects Measures of Systemic Inflammation: Reductions in High Sensitivity C-Reactive Protein Level and Neutrophil to Lymphocyte Ratio (NLR) Distribution. 2017 , 118, 4317-4322 | 41 |
| 156 | Outcomes of patients with chronic obstructive pulmonary disease diagnosed with or without pulmonary function testing. 2017 , 189, E530-E538 | 18 |
| 155 | Enrichment of Triglyceride-Rich Lipoproteins with Apolipoprotein C-I Is Positively Associated with Their Delayed Plasma Clearance Independently of Other Transferable Apolipoproteins in Postmenopausal Overweight and Obese Women. 2017 , 147, 754-762 | 3 |
| 154 | Rates of inappropriate laboratory test utilization in Ontario. 2017 , 50, 822-827 | 27 |
| 153 | Changes in high-density lipoprotein-carried miRNA contribution to the plasmatic pool after consumption of dietary trans fat in healthy men. 2017 , 9, 669-688 | 18 |
| 152 | Managing Cardiovascular Disease Risk in Rheumatoid Arthritis: Clinical Updates and Three Strategic Approaches. 2017 , 19, 16 | 21 |
| 151 | 2016 European Guidelines on cardiovascular disease prevention in clinical practice : The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). 2017 , 24, 321-419 | 54 |
| 150 | Effects of high-intensity aerobic interval training on cardiovascular disease risk in testicular cancer survivors: A phase 2 randomized controlled trial. 2017 , 123, 4057-4065 | 52 |
| 149 | Recent advances and clinical insights into the use of proteomics in the study of atherosclerosis. 2017 , 14, 701-713 | 4 |
| 148 | The ratio of serum n-3 to n-6 polyunsaturated fatty acids is associated with diabetes mellitus in patients with prior myocardial infarction: a multicenter cross-sectional study. 2017 , 17, 41 | 26 |
| 147 | An overview of maternal and fetal short and long-term impact of physical activity during pregnancy. 2017 , 295, 273-283 | 17 |
| 146 | Inflammation, cardiovascular disease and cancer: moving toward predictive medicine. 2017 , 189, E382-E383 | 2 |
| 145 | Incremental value of B-type natriuretic peptide for detection and risk reclassification of obstructive coronary artery disease on computed tomography angiography. 2017 , 69, 671-677 | 5 |
| 144 | Cardiometabolic Risk Factors in Childhood, Adolescent and Young Adult Survivors of Acute Lymphoblastic Leukemia - A Petale Cohort. 2017 , 7, 17684 | 28 |
| 143 | Psychometric analysis of the TRANSIT quality indicators for cardiovascular disease prevention in primary care. 2017 , 29, 999-1005 | 2 |
| 142 | Genomic determinants of long-term cardiometabolic complications in childhood acute lymphoblastic leukemia survivors. 2017 , 17, 751 | 12 |

| | | |
|-----|---|-----|
| 141 | Using Electronic Medical Record to Identify Patients With Dyslipidemia in Primary Care Settings: International Classification of Disease Code Matters From One Region to a National Database. 2017 , 9, 1178222616685880 | 14 |
| 140 | Preventive Cardiology. 2018 , 269-289 | |
| 139 | Stable Ischemic Heart Disease. 2018 , 591-630 | 2 |
| 138 | Framingham risk score and extent of atherosclerosis in non-diabetic patients with suspected coronary artery disease. 2018 , 8, 18-20 | 1 |
| 137 | Dyslipidaemia in the elderly: to treat or not to treat?. 2018 , 11, 259-278 | 5 |
| 136 | Family Health History and Health Risk Assessment For Cardiovascular Disease in Health Care. 2018 , 1-16 | 2 |
| 135 | Correlation Between Intron 4 Polymorphism of the Endothelial Nitric Oxide Synthase Gene and Cardiovascular Risk with the Numbers of Circulating Endothelial Progenitor Cells in Healthy Subjects. 2018 , 33, 202-207 | 0 |
| 134 | Effectiveness of Pharmacist Interventions on Cardiovascular Risk in Patients With CKD: A Subgroup Analysis of the Randomized Controlled REACH Trial. 2018 , 71, 42-51 | 13 |
| 133 | Association between chronic hepatitis B infection and metabolic syndrome. 2018 , 17, 223-232 | 3 |
| 132 | Cardiovascular Disease as a Result of the Interactions Between Obesity, Climate Change, and Inflammation: The COCCI Syndemic. 2018 , 118, 719-729 | 2 |
| 131 | Genetic associations in community context: a mixed model approach identifies a functional variant in the RBP4 gene associated with HDL-C dyslipidemia. 2018 , 19, 205 | 1 |
| 130 | A Mini-Review on Hyperlipidemia: Common Clinical Problem. 2018 , 04, | |
| 129 | DUSP1 Is a Potential Marker of Chronic Inflammation in Arabs with Cardiovascular Diseases. 2018 , 2018, 9529621 | 3 |
| 128 | The Use of High Sensitivity C-Reactive Protein in Cardiovascular Disease Detection. 2018 , 21, 496-503 | 27 |
| 127 | At what age do normal weight Canadian children become overweight adults? Differences according to sex and metric. 2018 , 45, 478-485 | 4 |
| 126 | Methyl-βcyclodextrin potentiates the BITC-induced anti-cancer effect through modulation of the Akt phosphorylation in human colorectal cancer cells. 2018 , 82, 2158-2167 | 6 |
| 125 | Associations Between Dietary Antioxidant Intake and Markers of Atherosclerosis in Middle-Aged Women From North-Western Algeria. 2018 , 5, 29 | 1 |
| 124 | Dairy Fats and Cardiovascular Disease: Do We Really Need to be Concerned?. 2018 , 7, | 127 |

| | | |
|-----|--|-------|
| 123 | Prospective cohort study of C-reactive protein as a predictor of clinical events in adults with congenital heart disease: results of the Boston adult congenital heart disease biobank. 2018 , 39, 3253-3261 | 26 |
| 122 | The Predictive Value of Arteriogenic Erectile Dysfunction for Coronary Artery Disease in Men. 2018 , 15, 880-887 | 4 |
| 121 | Ezetimibe prescriptions in older Canadian adults after an acute myocardial infarction: a population-based cohort study. 2018 , 17, 8 | 6 |
| 120 | Six-year time-trend analysis of dyslipidemia among adults in Newfoundland and Labrador: findings from the laboratory information system between 2009 and 2014. 2018 , 17, 99 | 4 |
| 119 | Simulation modeling to enhance population health intervention research for chronic disease prevention. 2019 , 110, 52-57 | 1 |
| 118 | Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society* Clinical Practice Guideline. 2019 , | 25 |
| 117 | Cardiovascular risk and encoding-related hippocampal connectivity in older adults. 2019 , 20, 37 | 2 |
| 116 | Association Between Endothelial Function and Cognitive Performance in Patients With Coronary Artery Disease During Cardiac Rehabilitation. 2019 , 81, 184-191 | 6 |
| 115 | Anticoagulation in Patients With Advanced Chronic Kidney Disease: Walking the Fine Line Between Benefit and Harm. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 1241-1255 | 3.8 5 |
| 114 | Concordance of care processes between medical records and patient self-administered questionnaires. 2019 , 20, 92 | 1 |
| 113 | A multi-scale model for low-density lipoprotein cholesterol (LDL-C) regulation in the human body: Application to quantitative systems pharmacology. 2019 , 130, 106507 | 8 |
| 112 | Chapitre 1 : Évaluation et gestion des risques chez les femmes ménopausées. 2019 , 41 Suppl 1, S36-S48 | |
| 111 | Au-delà du risque cardiovasculaire : le rôle des lipoprotéines contenant l'apoB athérogènes dans l'étiologie du diabète de type 2. 2019 , 13, 129-139 | 2 |
| 110 | The impact of monocyte to high-density lipoprotein ratio on reduced renal function: insights from a large population. 2019 , 13, 773-783 | 6 |
| 109 | Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol. 2019 , 18, 134 | 21 |
| 108 | A Bayesian multivariate latent t-regression model for assessing the association between corticosteroid and cranial radiation exposures and cardiometabolic complications in survivors of childhood acute lymphoblastic leukemia: a PETALE study. 2019 , 19, 100 | 3 |
| 107 | Lasso Regression for the Prediction of Intermediate Outcomes Related to Cardiovascular Disease Prevention Using the TRANSIT Quality Indicators. 2019 , 57, 63-72 | 12 |
| 106 | Cardiovascular Risk: Assumptions, Limitations, and Research. 2019 , 201-266 | |

| | | |
|-----|---|----|
| 105 | Altered proteome of high-density lipoproteins from paediatric acute lymphoblastic leukemia survivors. 2019 , 9, 4268 | 9 |
| 104 | Vasoprotective Functions of High-Density Lipoproteins Relevant to Alzheimer's Disease Are Partially Conserved in Apolipoprotein B-Depleted Plasma. 2019 , 20, | 4 |
| 103 | Cardiovascular Risk Reduction in the Workplace With CAMMPUS (Cardiovascular Assessment and Medication Management by Pharmacists at the UBC Site). 2019 , 53, 574-580 | 5 |
| 102 | Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies. 2020 , 41, 86-94 | 45 |
| 101 | Prevention of Long-term Adverse Health Outcomes With Cardiorespiratory Fitness and Physical Activity in Childhood Acute Lymphoblastic Leukemia Survivors. 2019 , 41, e450-e458 | 19 |
| 100 | Dietary Intakes Are Associated with HDL-Cholesterol in Survivors of Childhood Acute Lymphoblastic Leukaemia. 2019 , 11, | 5 |
| 99 | Diet Quality Is Associated with Cardiometabolic Outcomes in Survivors of Childhood Leukemia. 2020 , 12, | 8 |
| 98 | Nutrition Labeling Usage Influences Blood Markers in Body-Size Self-Conscious Individuals: The Korean National Health and Nutrition Examination Survey (KNHANES) 2013-2018. 2020 , 17, | 0 |
| 97 | Low-Density Lipoprotein Cholesterol and Adverse Cardiovascular Events After Percutaneous Coronary Intervention. 2020 , 76, 1440-1450 | 8 |
| 96 | Biomarkers of cardiometabolic complications in survivors of childhood acute lymphoblastic leukemia. 2020 , 10, 21507 | 0 |
| 95 | Real-world effectiveness of treatments for type 2 diabetes, hypercholesterolemia, and hypertension in Canadian routine care - Results from the CardioVascular and metabolic treatment in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry, 12-months results. 2020 , 170, 108416 | |
| 94 | Recent consumption of a caffeine-containing beverage and serum biomarkers of cardiometabolic function in the UK Biobank. 2021 , 126, 582-590 | 2 |
| 93 | Comparing effectiveness of high-dose Atorvastatin and Rosuvastatin among patients undergone Percutaneous Coronary Interventions: A non-concurrent cohort study in India. 2020 , 15, e0233230 | 5 |
| 92 | Impact of a 12-Week Randomized Exercise Training Program on Lipid Profile in Severely Obese Patients Following Bariatric Surgery. 2020 , 30, 3030-3036 | 5 |
| 91 | Nontargeted urine metabolomics analysis of the protective and therapeutic effects of Citri Reticulatae Chachiensis Pericarpium on high-fat feed-induced hyperlipidemia in rats. 2020 , 34, e4795 | 10 |
| 90 | What Is the Best Mix of Population-Wide and High-Risk Targeted Strategies of Primary Stroke and Cardiovascular Disease Prevention?. 2020 , 9, e014494 | 14 |
| 89 | Metrl deficiency decreases blood HDL cholesterol and increases blood triglyceride. 2020 , 41, 1568-1575 | 5 |
| 88 | A review of biosensor technologies for blood biomarkers toward monitoring cardiovascular diseases at the point-of-care. 2021 , 171, 112621 | 26 |

| | | |
|----|--|---|
| 87 | Lipoprotein and Lipid Metabolism. 2021 , 235-278 | 0 |
| 86 | Chronic kidney diseases among homeless and slum dwellers in Accra, Ghana. 2021 , 38, 340 | |
| 85 | Health measures of Eeyouch (Cree) who are eligible to participate in the on-the-land Income Security Program in Eeyou Istchee (northern Quebec, Canada). 2021 , 21, 628 | 2 |
| 84 | Molecular mechanism underlying the hypolipidemic effect of Shanmei Capsule based on network pharmacology and molecular docking. 2021 , 29, 239-256 | 6 |
| 83 | Association of chronic diseases with depression, anxiety and stress in Chinese general population: The CHCN-BTH cohort study. 2021 , 282, 1278-1287 | 6 |
| 82 | Cardiometabolic profile of type 2 diabetic subjects in Libreville. 2021 , 8, 15-21 | |
| 81 | Factors Associated With Nonreceipt of Recommended COPD Medications: A Population Study. 2021 , 160, 1670-1680 | |
| 80 | HDL-enriched miR-30a-5p is associated with HDL-cholesterol levels and glucose metabolism in healthy men and women. 2021 , 13, 985-994 | 2 |
| 79 | Cardiovascular Risk Stratification Based on Oxidative Stress for Early Detection of Pathology. 2021 , 35, 602-617 | 2 |
| 78 | Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group. 2021 , | 6 |
| 77 | Stable Ischemic Heart Disease. 2022 , 429-453 | |
| 76 | Preventive Cardiology. 2022 , 341-375 | |
| 75 | (Re)claiming our bodies using a Two-Eyed Seeing approach: Health-At-Every-Size (HAES [®]) and Indigenous knowledge. 2021 , 112, 493-497 | 4 |
| 74 | Effect of Multidisciplinary Dyslipidemia Educational Program on Adherence to Guidelines Directed Medical Therapy in Saudi Arabia. 2021 , 10, 35-41 | |
| 73 | Use of Combination Statin and Bile Acid Sequestrant Therapy to Treat Dyslipidemia. 2015 , 1-10 | 2 |
| 72 | Cardiovascular Dysfunction Following Spinal Cord Injury. 2017 , 325-361 | 2 |
| 71 | Disorders of Lipoprotein Metabolism. 2014 , 671-689 | 3 |
| 70 | Primary and Secondary Prevention of Coronary Heart Disease. 2012 , 1010-1035 | 4 |

| | | |
|----|--|----|
| 69 | [High sensitivity C protein as an independent risk factor in people with and without history of cardiovascular disease]. 2015 , 85, 124-35 | 7 |
| 68 | Use of once-weekly statin in combination with ezetimibe in a patient with mitochondrial disease. 2012 , 2012, | 1 |
| 67 | Cardiometabolic Risk Factors and Preclinical Target Organ Damage Among Adults in Ghana: Findings From a National Study. 2020 , 9, e017492 | 3 |
| 66 | The effect of omega-3 on serum lipid profile in hemodialysis patients. 2015 , 4, 68-72 | 4 |
| 65 | Effects of a Functional Electrical Stimulation-Assisted Cycling Program on Immune and Cardiovascular Health in Persons with Spinal Cord Injury. 2016 , 22, 71-78 | 4 |
| 64 | Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation. 2012 , 7, e41865 | 73 |
| 63 | Time variability of C-reactive protein: implications for clinical risk stratification. 2013 , 8, e60759 | 32 |
| 62 | Impact of the distance from the stent edge to the residual plaque on edge restenosis following everolimus-eluting stent implantation. 2015 , 10, e0121079 | 7 |
| 61 | Cardio-Metabolic Disease Risks and Their Associations with Circulating 25-Hydroxyvitamin D and Omega-3 Levels in South Asian and White Canadians. 2016 , 11, e0147648 | 8 |
| 60 | Long term health outcomes in patients with a history of myocardial infarction: A population based cohort study. 2017 , 12, e0180010 | 9 |
| 59 | Treatment gaps and potential cardiovascular risk reduction from expanded statin use in the US and England. 2018 , 13, e0190688 | 11 |
| 58 | Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy. 2015 , 3, 78-84 | 59 |
| 57 | Hyperlipidemia in rheumatoid arthritis patients in Saudi Arabia. Correlation with C-reactive protein levels and disease activity. 2015 , 36, 685-91 | 9 |
| 56 | Atorvastatin: evidence base 15 years later. 2011 , 10, 103-112 | 4 |
| 55 | The Role of Fructose, Sucrose and High-fructose Corn Syrup in Diabetes. 2014 , 10, 51-60 | 3 |
| 54 | Obesity risks: towards an emerging Inuit pattern. 2011 , 70, 166-77 | 22 |
| 53 | Controlling Lipids AIDs in the Prevention of Type 2 Diabetes, Hypertension, and Cardiovascular Diseases. 2017 , 8, 39 | 3 |
| 52 | JUPITER and satellites: Clinical implications of the JUPITER study and its secondary analyses. 2011 , 3, 207-14 | 7 |

- 51 Development of a Standardized Clinical Protocol for Ranking Foods and Meals Based on Postprandial Triglyceride Responses: The Lipemic Index. **2011**, 2011, 1-6 1
- 50 The Comparison of Guidelines for Management of Dyslipidemia and the Appropriateness of Them in Korea. **2010**, 31, 171 5
- 49 Treatment Principles and Emerging Therapies in Acute Coronary Syndromes without ST-Segment Elevation. **2011**, 194-200
- 48 Concepts of Screening for Cardiovascular Risk Factors and Disease. **2011**, 433-442
- 47 Intérêts des marqueurs biologiques dans les maladies cardiovasculaires. **2012**, 196, 217-222
- 46 The Effect of Attentional Bias Modification on the Cardiovascular Stress Reactivity. **2012**, 01, 10-14
- 45 Stable Ischemic Heart Disease. **2012**, 1210-1269
- 44 Risk Markers for Atherothrombotic Disease. **2012**, 914-934 4
- 43 Fibers and Prevention of Cardiovascular Disease. **2012**, 199-232
- 42 Biology of Aging and Implications for Heart Failure Therapy and Prevention. **2014**, 15-33
- 41 Role of Coronary Artery Calcium in Cardiovascular Risk Stratification and Management in the Aging Population. **2014**, 249-257
- 40 Evaluation of the Management of Hyperlipidemia and Hypertension in an Outpatient Cardiac Transplant Clinic. **2016**, 07, 71-80
- 39 6. Dietary cholesterol and the lack of evidence on heart disease risk. **2016**, 101-116
- 38 Predictive Value of Updating the Score Cardiovascular Risk Assessment Engine with Novel Biomarkers in a Type 2 Diabetes Population. **2016**, 23, 369-375
- 37 What did the European guidelines on cardiovascular disease prevention lose in clinical practice in 2016?. **2017**, 20, 7
- 36 A Comparison of Four Cardiovascular Risk Assessment Instruments in Saudi Patients. **2020**, 12, e7093 1
- 35 Cardiometabolic risk factors and preclinical target organ damage among adults in Ghana: Findings from a national study.
- 34 Cardiovascular disease risk prediction for people with type 2 diabetes in a population-based cohort and in electronic health record data. **2020**, 3, 583-592 2

| | | |
|----|--|----|
| 33 | Inflammation, high-sensitivity C-reactive protein, and vascular protection. 2010 , 37, 40-1 | 7 |
| 32 | Practical use of the Framingham risk score in primary prevention: Canadian perspective. 2011 , 57, 417-23 | 34 |
| 31 | How applicable are clinical practice guidelines to elderly patients with comorbidities?. 2011 , 57, e253-62 | 66 |
| 30 | Annual adult health checkup: update on the Preventive Care Checklist Form("). 2012 , 58, 43-7 | 6 |
| 29 | Implications of a newer Framingham model. 2012 , 58, 378-9; author reply 379-80 | |
| 28 | Managing cardiometabolic risk in primary care: summary of the 2011 consensus statement. 2012 , 58, 389-93, e196-201 | 16 |
| 27 | Niacin added to statins for cardiovascular disease. 2012 , 58, 842 | |
| 26 | How diet modification challenges are magnified in vulnerable or marginalized people with diabetes and heart disease: a systematic review and qualitative meta-synthesis. 2013 , 13, 1-40 | 18 |
| 25 | Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes. 2013 , 59, 1169-80 | 35 |
| 24 | Discrepancies between two lipid-lowering guidelines for CVD prevention in seemingly healthy individuals-case study Lebanon. 2013 , 3, 129-36 | 2 |
| 23 | Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes. 2013 , 138, 461-91 | 13 |
| 22 | Dietary phytochemical index and subsequent changes of lipid profile: A 3-year follow-up in Tehran Lipid and Glucose Study in Iran. 2014 , 10, 203-10 | 18 |
| 21 | High-sensitive factor I and C-reactive protein based biomarkers for coronary artery disease. 2014 , 7, 5158-69 | 1 |
| 20 | PURLs: skip this step when checking lipid levels. 2015 , 64, 113-5 | |
| 19 | Frequency of Testing for Dyslipidemia: An Evidence-Based Analysis. 2014 , 14, 1-30 | |
| 18 | Health screening for older people-what are the current recommendations?. 2015 , 10, 2-10 | 4 |
| 17 | Performance of an integrated network model: Evaluation of the first 4 years. 2016 , 62, e448-56 | |
| 16 | Assessing family history of chronic disease in primary care: Prevalence, documentation, and appropriate screening. 2017 , 63, e58-e67 | 12 |

- 15 Statin-prescribing trends for primary and secondary prevention of cardiovascular disease. **2017**, 63, e495-e503 16
- 14 Cardiovascular risk factor documentation and management in primary care electronic medical records among people with schizophrenia in Ontario, Canada: retrospective cohort study. **2020**, 10, e038013
- 13 Cardiovascular risk factor documentation and management in primary care electronic medical records among people with schizophrenia in Ontario, Canada: retrospective cohort study. **2020**, 10, e038013 ○
- 12 Innovative Approaches to Assess Intermediate Cardiovascular Risk Subjects: A Review From Clinical to Metabolomics Strategies.. **2021**, 8, 788062 1
- 11 Comparison between Policaptil Gel Retard and Metformin by Testing of Temporal Changes in Patients with Metabolic Syndrome and Type 2 Diabetes. **2022**, 3, 315-327
- 10 High-Sensitivity C-Reactive Protein. **2022**, 347-375
- 9 The risk factors for radial artery and saphenous vein graft occlusion are different. *Scandinavian Cardiovascular Journal*, **2022**, 56, 127-131 2
- 8 Tackling Atherosclerosis via Selected Nutrition. **2022**, 23, 8233 1
- 7 Effects of a person-centred, nurse-led follow-up programme on adherence to prescribed medication among patients surgically treated for intermittent claudication: randomized clinical trial. **2022**, 109, 846-856 ○
- 6 What should be the goal of cholesterol-lowering treatment? A quantitative evaluation dispelling guideline myths. **2022**, 33, 219-226 ○
- 5 The Association Between Vitamin D Levels and the 10-Year Risk of Atherosclerotic Cardiovascular Disease. Publish Ahead of Print, ○
- 4 Prevalence of Arterial Stiffness Determined by Cardio-ankle Vascular Index in Myeloproliferative Neoplasms. ○
- 3 Effect of *Allium sativum* and *Olea europaea* on serum lipids in patients with diabetes mellitus. **2022**, ○
- 2 Primary Care Clinical Volumes, Cholesterol Testing, and Cardiovascular Outcomes. **2022**, ○
- 1 Do blood metals influence lipid profiles? Findings of a cross-sectional population-based survey. **2023**, 116107 ○